Neurocrine Biosciences Balance Sheet
NBIX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Neurocrine Biosciences had $4.6B in total assets and $3.3B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M | $187.1M | $112.3M | $141.7M | $254.7M | $83.3M | $74.2M | $31.0M | $44.8M | $63.8M | $50.1M |
| Accounts Receivable | $686.8M | $479.1M | $439.3M | $350.0M | $185.5M | $157.1M | $126.6M | $57.4M | $31.1M | $0 | - | - | - | - | - |
| Inventory | $69.0M | $57.4M | $38.3M | $35.1M | $30.5M | $28.0M | $17.3M | $10.9M | $1.0M | - | - | - | - | - | - |
| Current Assets | $2.5B | $1.7B | $1.6B | $1.5B | $972.8M | $1.0B | $831.0M | $737.8M | $554.9M | $310.4M | $384.1M | $198.2M | $148.5M | $189.3M | $132.5M |
| PP&E (Net) | $89.8M | $82.6M | $70.8M | $58.6M | $58.6M | $44.6M | $41.9M | $33.9M | $10.8M | $6.3M | $3.4M | $2.5M | $1.8M | $1.9M | $1.6M |
| Goodwill | - | $5.7M | $5.8M | $5.4M | $0 | - | - | - | - | - | - | - | - | - | - |
| Total Assets | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B | $1.7B | $1.3B | $993.2M | $817.6M | $365.1M | $474.8M | $243.0M | $154.7M | $196.0M | $138.4M |
| Current Liabilities | $743.4M | $507.7M | $654.8M | $537.7M | $245.8M | $186.5M | $565.3M | $88.2M | $54.4M | $30.4M | $25.7M | $15.7M | $11.7M | $15.6M | $47.1M |
| Shareholders' Equity | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B | $1.1B | $636.9M | $480.8M | $372.2M | $314.9M | $424.5M | $208.7M | $120.4M | $154.4M | $60.1M |